Kiener Peter A 4
4 · Cue Biopharma, Inc. · Filed Mar 27, 2023
Insider Transaction Report
Form 4
Kiener Peter A
Director
Transactions
- Exercise/Conversion
Common Stock
2023-03-23$2.86/sh+9,682$27,691→ 9,682 total - Exercise/Conversion
Stock Option (right to buy)
2023-03-23−9,682→ 96,062 totalExercise: $2.86Exp: 2023-03-23→ Common Stock (9,682 underlying) - Sale
Common Stock
2023-03-23$3.28/sh−9,325$30,586→ 357 total
Footnotes (3)
- [F1]Sale to cover exercise price of cashless exercise of stock option.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]This Stock Option became exercisable in five equal annual installments beginning March 23, 2017 and is fully vested. This stock option expired on March 23, 2023.